Levamisole as an Adjuvant to Short-Course Therapy in Newly Diagnosed Pulmonary Tuberculosis Patients

Shamkuwar, Chetna Ashok; Meshram, Sushant Hiraman; Mahakalkar, Sunil M

Levamisole as an Adjuvant to Short-Course Therapy in Newly Diagnosed Pulmonary Tuberculosis Patients

Document Type : Original Article

Authors

¹ Department of Pharmacology, Government Medical College, Chandrapur, Maharashtra, India

² Department of Respiratory Medicine, B.J. Medical College, Pune, Maharashtra, India

³ Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India

Abstract

Background: The estimated incidence and prevalence of tuberculosis in India are 2.1 and 2.6 million cases respectively. Immunotherapy may shorten tuberculosis treatments and improve the immunity of individuals as well. Hence we study the efficacy of levamisole (LVM) (immunomodulator) as an adjuvant to chemotherapy of pulmonary tuberculosis patients. Materials and Methods: A randomized, double-blind, placebo-controlled clinical trial was conducted for 21 months in newly diagnosed sputum positive pulmonary tuberculosis patients. Patients were subjected initially to clinical examination, sputum acid-fast bacilli smear and culture, tuberculin skin test and weight record. During follow-up, above investigations were repeated. Sixty-five patients were randomly assigned into two groups to receive either tab LVM 100 mg once in a day or matching placebo, orally as a single dose, thrice a week, for 2 months with short-course antituberculosis chemotherapy. Results: Sputum negativity at 1 week was observed in 11 (44%) patients in LVM group whereas only 3 (12%) in placebo group. All the patients 25 (100%) in LVM group were sputum negative compared to 14 (56%) in placebo group by the end of 3 weeks. In LVM group, 24 (96%) and 11 (44%) patients in placebo group show radiological improvement at 2 months. A direct correlation existed between quantum of immune response and weight gain with LVM. LVM rendered all anergic patients to positive tuberculin reactors. In LVM group, patients with initial Mantoux ≥20 mm and advanced cavitary disease, there was decrease in tuberculin reaction size. Conclusion: Adjuvant immunomodulation with levamisole has the potential of shortening the total duration of antitubercular therapy.

Keywords

References

1.	Cox HS, Orozco JD, Male R, Ruesch-Gerdes S, Falzon D, Small I, et al. Multidrug-resistant tuberculosis in central Asia. Emerg Infect Dis 2004;10:865-72.
2.	World Health Organization. WHO Report on TB. Geneva: The World Health Organization; 2003.
3.	Espinal MA. The global situation of MDR-TB. Tuberculosis (Edinb) 2003;83:44-51.
4.	Seah GT, Scott GM, Rook GA. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 2000;181:385-9.
5.	Sirenko IA, Nastas PN. Use of levamisole electrophoresis in chemical prophylaxis in adolescents with a change in tuberculin reaction. Probl Tuberk 1993;3:30-3.
6.	Youmans GP. Development of delayed (tuberculin) hypersensitivity in tuberculosis. In: Yomans GP, Paterson PY, Sommers HM, editors. The Biological and Clinical Basis of Infectious Disease. 3^rd ed. Philadelphia: WB Saunders Company; 1985. p. 355-8.
7.	Stites DP, Holds JD, Schmitz J. Clinical laboratory method for detection of cellular immunity. In: Stites DP, Terr AI, Parslow TG, editors. Medical Immunology. 9^th ed. Appleton and Lange: A Simon and Schuster Company; 1997. p. 255.
8.	Addington WW. Patient compliance: The most serious remaining problem in the control of tuberculosis in the United States. Chest 1979;76 6 Suppl: 741-3.
9.	Second East African/British Medical Research Council Report. Controlled clinical trial of four short-course (6 months) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1974;1:1100-8.
10.	Renoux G. The general immunopharmacology of levamisole. Drugs 1980;20:89-99.
11.	Stanford JL, Bahr GM, Byass P, Corrah T, Dowlati Y, Lucas S, et al. A modern approach to the immunotherapy of tuberculosis. Bull Int Union Tuberc Lung Dis 1990;65:27-9.
12.	Etemadi A, Farid R, Stanford JL. Immunotherapy for drug-resistant tuberculosis. Lancet 1992;340:1360-1.
13.	Maher D, Chaulet P, Spinaci S, Harries A. Treatment of Tuberculosis: Guidelines for National Programmes. 2^nd ed Geneva: World Health Organisation; 1997 WHO/TB/97. 220:59.
14.	Singh MM, Kumar P, Malaviya AN, Kumar R. Levamisole as an adjunct in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1981;123:277-9.
15.	Wilsher ML, Hagan C, Prestidge R, Wells AU, Murison G. Human in vitro immune responses to Mycobacterium tuberculosis. Tuber Lung Dis 1999;79:371-7.
16.	Ellner JJ. Regulation of the human cellular immune response to Mycobacterium tuberculosis. The mechanism of selective depression of the response to PPD. Bull Int Union Tuberc Lung Dis 1991;66:129-32.
17.	Takahashi S, Setoguchi Y, Nukiwa T, Kira S. Soluble interleukin-2 receptor in sera of patients with pulmonary tuberculosis. Chest 1991;99:310-4.
18.	Sodhi A, Gong J, Silva C, Qian D, Barnes PF. Clinical correlates of interferon gamma production in patients with tuberculosis. Clin Infect Dis 1997;25:617-20.
19.	Huygen K, Van Vooren JP, Turneer M, Bosmans R, Dierckx P, De Bruyn J. Specific lymphoproliferation, gamma interferon production, and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis. Scand J Immunol 1988;27:187-94.
20.	Van Crevel R, Karyadi E, Preyers F, Leenders M, Kullberg BJ, Nelwan RH, et al. Increased production of interleukin 4 by CD4+and CD8+T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J Infect Dis 2000;181:1194-7.
21.	Hernandez-Pando R, Rook GA. The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 1994;82:591-5.
22.	Grange JM. The microanatomical nature of the tuberculin reaction. In: Narang P, Mendiratta DK, editors. Proceedings of International CME on Tuberculosis. Sevagram, India: MGIMS; 1996. p. 11-19.
23.	Toman K. Tuberculosis case finding and chemotherapy. Geneva: WHO; 1979. p. 151.
24.	Vanham G, Toossi Z, Hirsch CS, Wallis RS, Schwander SK, Rich EA, et al. Examining a paradox in the pathogenesis of human pulmonary tuberculosis: Immune activation and suppression/anergy. Tuber Lung Dis 1999;79:371-7.
25.	Santucci MB, Amicosante M, Ciccani R, Montesano C, Casarini M, et al. Mycobacterium tuberculosis induced apoptosis in monocytes/macrophages: Early membrane modification and intracellular mycobacterial viability. J Infect Dis 2000;181:1506-9.
26.	Ganiev KG, Vavilova TA. Use of differentiated pathogenetic therapy in the treatment of newly detected pulmonary tuberculosis in adolescents and young persons. Probl Tuberk 1990;9:35-6.
27.	Youmans GP. Tuberculosis. 1^st ed. Philadelphia: WB Saunders Company; 1979. p. 202-9.
28.	Szeto C, Gillespie KM, Mathieson PW. Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 2000;100:217-24.
29.	Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, Lewis FA, et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995;376:594-6.
30.	Renoux G. Modulation of immunity by levamisole. J Pharmacol Ther 1978:2:288-96.
31.	Turk JL, Parker D. Sensitization of guinea pigs to levamisole. Int Arch Allergy Appl Immunol 1979;58:237-40.
32.	Mielants H, Veys EM. A study of the hematological side effects of levamisole in rheumatoid arthritis with recommendations. J Rheumatol 1978;4:77-83.
33.	Donald PR, Lamprecht JH, Freestone M, Albrecht CF, Bouic PJ, Kotze D, et al. A randomised placebo-controlled trial of the efficacy of beta – Sitosterol and its glucoside as adjuvants in the treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 1997;1:518-22.
34.	Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. Newly-diagnosed pulmonary disease. Respir Med 1997;91:13-9.

Advanced Biomedical Research